Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
9.75
-0.02 (-0.20%)
At close: Jul 19, 2024, 4:00 PM
9.69
-0.06 (-0.62%)
Pre-market: Jul 22, 2024, 7:11 AM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ARQT stock have an average target of 26.17, with a low estimate of 10 and a high estimate of 50. The average target predicts an increase of 168.41% from the current stock price of 9.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ARQT stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +84.62% | Jul 10, 2024 |
| Needham | Needham | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | +84.62% | May 15, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $17 → $18 | Strong Buy | Maintains | $17 → $18 | +84.62% | May 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +64.10% | Apr 12, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $6 → $11 | Hold | Maintains | $6 → $11 | +12.82% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
167.31M
from 59.61M
Increased by 180.69%
Revenue Next Year
251.29M
from 167.31M
Increased by 50.19%
EPS This Year
-1.94
from -3.78
EPS Next Year
-1.24
from -1.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 190.9M | 291.9M | 466.2M | 741.3M | 1,000.0M |
| Avg | 167.3M | 251.3M | 421.2M | 599.7M | 757.6M |
| Low | 148.0M | 203.7M | 364.5M | 525.5M | 628.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 220.2% | 74.4% | 85.5% | 76.0% | 66.7% |
| Avg | 180.7% | 50.2% | 67.6% | 42.4% | 26.3% |
| Low | 148.3% | 21.8% | 45.0% | 24.8% | 4.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.68 | -1.09 | 0.28 | 2.61 | 4.56 |
| Avg | -1.94 | -1.24 | -0.25 | 1.29 | 2.24 |
| Low | -3.08 | -1.49 | -0.54 | 0.59 | 1.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 253.5% |
| Avg | - | - | - | - | 73.7% |
| Low | - | - | - | - | -22.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.